仿制药-话题@MedSci

#仿制药#

261篇内容 | 5525人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1261514, encodeId=f66d1261514f3, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=诺华的长效化重组人粒细胞集落刺激因子生物仿制药Ziextenzo获得FDA批准上市, objectType=article, longId=182505, objectId=788918250583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=788918250583, replyNumber=0, likeNumber=117, createdTime=2019-11-08, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=788918250583, moduleTitle=诺华的长效化重组人粒细胞集落刺激因子生物仿制药Ziextenzo获得FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=788918250583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261513, encodeId=5f7712615135b, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=天士力右佐匹克隆片获仿制药一致性评价, objectType=article, longId=181837, objectId=de8018183e17, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de8018183e17, replyNumber=0, likeNumber=59, createdTime=2019-10-25, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de8018183e17, moduleTitle=天士力右佐匹克隆片获仿制药一致性评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de8018183e17)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261512, encodeId=abb7126151282, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA创新记录，2019年批准了1171个仿制药, objectType=article, longId=181806, objectId=8a6d1818063f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a6d1818063f, replyNumber=0, likeNumber=86, createdTime=2019-10-25, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a6d1818063f, moduleTitle=FDA创新记录，2019年批准了1171个仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a6d1818063f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261511, encodeId=e9b112615117b, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=化学药品注射剂仿制药一致性评价技术要求征求意见, objectType=article, longId=181345, objectId=f93918134574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f93918134574, replyNumber=0, likeNumber=72, createdTime=2019-10-18, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f93918134574, moduleTitle=化学药品注射剂仿制药一致性评价技术要求征求意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f93918134574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261510, encodeId=b0131261510a4, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药不挣钱、创新赛道拥挤......国内药企转型之路在哪儿？, objectType=article, longId=181025, objectId=7f39181025ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f39181025ea, replyNumber=0, likeNumber=61, createdTime=2019-10-14, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f39181025ea, moduleTitle=仿制药不挣钱、创新赛道拥挤......国内药企转型之路在哪儿？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f39181025ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261509, encodeId=b0c01261509e6, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=龙头药企集体放弃仿制药，4+7扩围后，仿制药进入微利时代, objectType=article, longId=181020, objectId=e55b18102049, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e55b18102049, replyNumber=0, likeNumber=61, createdTime=2019-10-14, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e55b18102049, moduleTitle=龙头药企集体放弃仿制药，4+7扩围后，仿制药进入微利时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e55b18102049)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261508, encodeId=36c9126150890, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=第一批鼓励仿制药品目录发布, objectType=article, longId=180808, objectId=6697180808ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6697180808ea, replyNumber=0, likeNumber=57, createdTime=2019-10-11, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6697180808ea, moduleTitle=第一批鼓励仿制药品目录发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6697180808ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261507, encodeId=79f6126150e99, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药的未来在何方？, objectType=article, longId=180254, objectId=07bd180254a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07bd180254a8, replyNumber=0, likeNumber=76, createdTime=2019-10-01, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07bd180254a8, moduleTitle=仿制药的未来在何方？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07bd180254a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261506, encodeId=b9a71261506f8, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=信达生物的TNF单抗仿制药IBI303治疗强直性脊柱炎，与修美乐疗效和安全性相当, objectType=article, longId=178540, objectId=b7281e8540c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7281e8540c0, replyNumber=0, likeNumber=121, createdTime=2019-09-03, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7281e8540c0, moduleTitle=信达生物的TNF单抗仿制药IBI303治疗强直性脊柱炎，与修美乐疗效和安全性相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7281e8540c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261505, encodeId=35771261505e6, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=走，去中国！4家印度药企巨头集结，杀入5000亿仿制药市场, objectType=article, longId=178502, objectId=bc621e85024c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc621e85024c, replyNumber=0, likeNumber=65, createdTime=2019-09-02, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc621e85024c, moduleTitle=走，去中国！4家印度药企巨头集结，杀入5000亿仿制药市场, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc621e85024c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261504, encodeId=313d126150475, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=AP&T：英夫利昔单抗与生物仿制药CT-P13在溃疡性结肠炎患者中的有效性和安全性比较, objectType=article, longId=177412, objectId=02521e741284, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02521e741284, replyNumber=0, likeNumber=68, createdTime=2019-08-12, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02521e741284, moduleTitle=AP&T：英夫利昔单抗与生物仿制药CT-P13在溃疡性结肠炎患者中的有效性和安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02521e741284)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261503, encodeId=233a1261503f5, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA对抗体生物仿制药产品批准在2019年明显增加, objectType=article, longId=177386, objectId=08bb1e7386a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08bb1e7386a4, replyNumber=0, likeNumber=79, createdTime=2019-08-12, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08bb1e7386a4, moduleTitle=FDA对抗体生物仿制药产品批准在2019年明显增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08bb1e7386a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261502, encodeId=985b1261502d8, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=印度“强仿制药”巨头再次进入中国市场，机遇还是挑战？, objectType=article, longId=176252, objectId=7fdc1e625200, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fdc1e625200, replyNumber=0, likeNumber=62, createdTime=2019-07-28, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fdc1e625200, moduleTitle=印度“强仿制药”巨头再次进入中国市场，机遇还是挑战？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fdc1e625200)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261501, encodeId=8aaa1261501a7, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药一致性评价受理号达1289个通过308个, objectType=article, longId=175790, objectId=286d1e5790a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=286d1e5790a5, replyNumber=0, likeNumber=75, createdTime=2019-07-21, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=286d1e5790a5, moduleTitle=仿制药一致性评价受理号达1289个通过308个, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=286d1e5790a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261500, encodeId=09a112615000c, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药市场大清洗 141家药企强制降价**87%, objectType=article, longId=175751, objectId=e7171e57518a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7171e57518a, replyNumber=0, likeNumber=56, createdTime=2019-07-20, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7171e57518a, moduleTitle=仿制药市场大清洗 141家药企强制降价**87%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7171e57518a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261499, encodeId=05f0126149905, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=国家鼓励生产34种仿制药，涉罕见病、癌症等用药，或将降低药费, objectType=article, longId=175534, objectId=99dd1e553474, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99dd1e553474, replyNumber=0, likeNumber=69, createdTime=2019-07-17, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99dd1e553474, moduleTitle=国家鼓励生产34种仿制药，涉罕见病、癌症等用药，或将降低药费, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99dd1e553474)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261498, encodeId=f0a3126149843, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Arthritis Rheumatol：培化舍珠单抗、阿巴西普和英夫利昔单抗生物仿制药治疗类风湿性关节炎的疗效比较, objectType=article, longId=175232, objectId=9d501e52321e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d501e52321e, replyNumber=0, likeNumber=62, createdTime=2019-07-13, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d501e52321e, moduleTitle=Arthritis Rheumatol：培化舍珠单抗、阿巴西普和英夫利昔单抗生物仿制药治疗类风湿性关节炎的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d501e52321e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261497, encodeId=458d126149e74, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药的阴影下不只法律一个问题, objectType=article, longId=172224, objectId=da101e222492, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da101e222492, replyNumber=0, likeNumber=83, createdTime=2019-06-28, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da101e222492, moduleTitle=仿制药的阴影下不只法律一个问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da101e222492)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261496, encodeId=f243126149633, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=抗癌药入选首批鼓励仿制药建议清单, objectType=article, longId=172176, objectId=c0181e217653, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0181e217653, replyNumber=0, likeNumber=78, createdTime=2019-06-27, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0181e217653, moduleTitle=抗癌药入选首批鼓励仿制药建议清单, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0181e217653)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261495, encodeId=054f126149580, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=上海GPO模式获肯定，推广之后大批仿制药恐遭淘汰, objectType=article, longId=168823, objectId=54f91688234d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54f91688234d, replyNumber=0, likeNumber=70, createdTime=2019-06-22, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54f91688234d, moduleTitle=上海GPO模式获肯定，推广之后大批仿制药恐遭淘汰, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54f91688234d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

仿制药

2020-05-29

drwjr (审核中...)

前往app查看评论内容

#仿制药#

诺华的长效化重组人粒细胞集落刺激因子生物仿制药Ziextenzo获得FDA批准上市

2019-11-08

drwjr (审核中...)

前往app查看评论内容

#仿制药#

天士力右佐匹克隆片获仿制药一致性评价

2019-10-25

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA创新记录，2019年批准了1171个仿制药

2019-10-25

drwjr (审核中...)

前往app查看评论内容

#仿制药#

化学药品注射剂仿制药一致性评价技术要求征求意见

2019-10-18

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药不挣钱、创新赛道拥挤......国内药企转型之路在哪儿？

2019-10-14

drwjr (审核中...)

前往app查看评论内容

#仿制药#

龙头药企集体放弃仿制药，4+7扩围后，仿制药进入微利时代

2019-10-14

drwjr (审核中...)

前往app查看评论内容

#仿制药#

第一批鼓励仿制药品目录发布

2019-10-11

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药的未来在何方？

2019-10-01

drwjr (审核中...)

前往app查看评论内容

#仿制药#

信达生物的TNF单抗仿制药IBI303治疗强直性脊柱炎，与修美乐疗效和安全性相当

2019-09-03

drwjr (审核中...)

前往app查看评论内容

#仿制药#

走，去中国！4家印度药企巨头集结，杀入5000亿仿制药市场

2019-09-02

drwjr (审核中...)

前往app查看评论内容

#仿制药#

AP&T：英夫利昔单抗与生物仿制药CT-P13在溃疡性结肠炎患者中的有效性和安全性比较

2019-08-12

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA对抗体生物仿制药产品批准在2019年明显增加

2019-08-12

drwjr (审核中...)

前往app查看评论内容

#仿制药#

印度“强仿制药”巨头再次进入中国市场，机遇还是挑战？

2019-07-28

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药一致性评价受理号达1289个通过308个

2019-07-21

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药市场大清洗 141家药企强制降价**87%

2019-07-20

drwjr (审核中...)

前往app查看评论内容

#仿制药#

国家鼓励生产34种仿制药，涉罕见病、癌症等用药，或将降低药费

2019-07-17

drwjr (审核中...)

前往app查看评论内容

#仿制药#

Arthritis Rheumatol：培化舍珠单抗、阿巴西普和英夫利昔单抗生物仿制药治疗类风湿性关节炎的疗效比较

2019-07-13

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药的阴影下不只法律一个问题

2019-06-28

drwjr (审核中...)

前往app查看评论内容

#仿制药#

抗癌药入选首批鼓励仿制药建议清单

2019-06-27

drwjr (审核中...)

前往app查看评论内容

#仿制药#

上海GPO模式获肯定，推广之后大批仿制药恐遭淘汰

2019-06-22

科室
- - 订阅+
  - 更多科室
工具
服务